It’s always reassuring listening to Dr. Patterso

It’s always reassuring listening to Dr. Patterson and Dr. Yo discussing the science of Leronlimab. Besides good news on covid and HIV, you got to be excited about Leronlimab’s prospect in cancer combining with checkpoint inhibitors (PD1, PDL1, CTLA-4), CDK4/6 inhibitors, and CAR-T (to address cytokine release syndrome) and potential partnerships (think of Merck, BMS, Roche, Lilly, Pfizer). Per Dr. Patterson and Dr. Drew, “1-2 punch”. An example of such collaboration was in 2018 in which BMS shelled out $1.85 billion up front to Nektar Therapeutics for development and commercial collaboration for Nektar lead compound in several tumor types. https://news.bms.com/press-release/partnering...-developme

I’m also encouraged to see Cytodyn listed their NASH study on clinicaltrials.gov this morning https://clinicaltrials.gov/ct2/show/NCT045211...amp;rank=2 (start date anticipated Oct1,2020). There is no approved drugs in this huge untapped market, with several recent failures (yes, Gilead 2 phase 3 trials 2019, Genfit phase 3 trial 2020, FDA rejection of Intercept phase 3 data). And so many other indications planned in future that I lost count including GvHD, inflammation diseases, MS, Alzheimer’s,...